Anika Therapeutics (ANIK) Current Deferred Revenue (2010 - 2026)

Anika Therapeutics' (ANIK) quarterly Current Deferred Revenue came in at $229000.0 in Q1 2026, up 340.38% on a QoQ basis from $52000.0 in Q3 2018.

Anika Therapeutics (ANIK) Current Deferred Revenue (2010 - 2026) Analysis & Trends

Anika Therapeutics (ANIK) has 8 years of Current Deferred Revenue data on file, last reported at $229000.0 in Q1 2026.

On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $229000.0 in Q1 2026; TTM through Mar 2026 was $229000.0, a N/A change from a year earlier, with the FY2014 full-year figure at $24510.0, down 98.9% from the prior year.
Current Deferred Revenue for Q1 2026 stood at $229000.0, up from $52000.0 in the prior quarter.
Over the last five years, Current Deferred Revenue for ANIK reached as high as $229000.0 in Q1 2026 and fell as low as $229000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Anika Therapeutics	198.50 Mn	131.71 Mn	19.00 Mn

Download Data